Innoviva (INVA) Other Working Capital Changes (2010 - 2026)

Innoviva (INVA) posted Other Working Capital Changes of -$126000.0 for Q3 2019, down 6400.0% on a QoQ basis from $2000.0 in Q2 2018.

Innoviva (INVA) Other Working Capital Changes (2010 - 2026) Analysis & Trends

Innoviva's Other Working Capital Changes history runs 5 years deep, the most recent figure standing at -$126000.0 for Q3 2019.

Quarterly Other Working Capital Changes changed N/A year-over-year to -$126000.0 in Q3 2019, while the trailing twelve-month figure through Dec 2020 was -$126000.0 (changed 0.0% YoY) and the FY2019 annual result came in at -$126000.0, down 3250.0% from the prior year.
Other Working Capital Changes was -$126000.0 for Q3 2019 at Innoviva, down from $2000.0 in the prior quarter.
Across five years, Other Working Capital Changes topped out at $1.7 million in Q2 2023 and bottomed at -$1.8 million in Q3 2023.
A 5-year average of -$433416.7 and a median of -$593500.0 in 2024 frame the typical range for Other Working Capital Changes.
Annual changes were most pronounced in 2016 — Other Working Capital Changes soared 4100.0% — and 2017, when it tumbled 51966.67%.
Innoviva's Other Working Capital Changes stood at -$2000.0 in 2015, then surged by 400.0% to $6000.0 in 2016, then tumbled by 51966.67% to -$3.1 million in 2017, then surged by 100.06% to $2000.0 in 2018, then slumped by 6400.0% to -$126000.0 in 2019.
Business Quant data shows INVA's Other Working Capital Changes at -$126000.0 in Q3 2019, $2000.0 in Q2 2018, and $2000.0 in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Innoviva	1.57 Bn	969.11 Mn	75.83 Mn

Download Data